Cargando…

Analysis of patient access to orphan drugs in Turkey

BACKGROUND: Rare diseases are life-threatening, serious, and chronic conditions that require complex care and have a low prevalence. An estimated one in 15 people worldwide are affected by rare diseases. This study aims to analyze the accessibility, reimbursement status, licensed status, and Anatomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koçkaya, Güvenç, Atalay, Sibel, Oğuzhan, Gülpembe, Kurnaz, Mustafa, Ökçün, Selin, Sar Gedik, Çiğdem, Şaylan, Mete, Şencan, Nazlı
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868010/ https://www.ncbi.nlm.nih.gov/pubmed/33549137 http://dx.doi.org/10.1186/s13023-021-01718-3

Ejemplares similares

Out-of-pocket healthcare expenditures of Turkish households living with rare diseases
por: Koçkaya, Güvenç, et al.
Publicado: (2023)

Changes in Catastrophic Health Expenditures Depending on Health Policies in Turkey
por: Kockaya, Guvenc, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of the Triclip™ Transcatheter Tricuspid Valve Repair System in Patients with Tricuspid Regurgitation
por: Kurnaz, Mustafa, et al.
Publicado: (2022)

PIN56 Cost of COVID-19 Patients Treatment in Turkey
por: Karahan, E.B., et al.
Publicado: (2020)

PIN8 A MODEL for Estimation of Possible COVID-19 Patient Numbers in Turkey
por: Öztopçu, S., et al.
Publicado: (2020)

Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey
por: Kockaya, Guvenc, et al.
Publicado: (2015)

Mechanism of coordinated access to orphan drugs
por: DeRidder, R, et al.
Publicado: (2012)

Patient access to orphan drugs in France
por: Bourdoncle, Marion, et al.
Publicado: (2019)

ABO and Rh Blood Group Distribution in Kayseri Province, Turkey
por: Torun, Yasemin Altuner, et al.
Publicado: (2012)

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)

Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina
por: Guzvic, Vladmiri, et al.
Publicado: (2018)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Market access of orphan drugs and the role of multi-criteria decision making
por: Simoens, Steven
Publicado: (2012)

Access to Orphan Drugs is a Challenge for Sustainable Management of Cystinosis in China
por: Li, Xiao-Qiao, et al.
Publicado: (2018)

The Ski Climate Index (SCI): fuzzification and a regional climate modeling application for Turkey
por: Demiroglu, Osman Cenk, et al.
Publicado: (2020)

Description of Pediatric Tuberculosis Evaluated in a Referral Center in Istanbul Turkey
por: Gulec, Seda Geylani, et al.
Publicado: (2012)

Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement
por: Jakovljevic, Mihajlo, et al.
Publicado: (2021)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
por: Gammie, Todd, et al.
Publicado: (2015)

Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022
por: Liu, Jia, et al.
Publicado: (2023)

Natural Radionuclides in Bottled Mineral Waters Consumed in Turkey and Their Contribution to Radiation Dose
por: Altıkulaç, Aydan, et al.
Publicado: (2022)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Compassionate use of orphan drugs
por: Hyry, Hanna I., et al.
Publicado: (2015)

Orphan drugs: Indian perspective
por: Kumar, Harish, et al.
Publicado: (2017)

Are we using drugs rationally? A survey study from Turkey
por: Ozdinc, Serife, et al.
Publicado: (2015)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Cost of heart failure management in Turkey: results of a Delphi Panel
por: Aras, Dursun, et al.
Publicado: (2016)

Dataset on social and psychological effects of COVID-19 pandemic in Turkey
por: Sari, Emre, et al.
Publicado: (2022)

Triggering drug use in patients with psoriasis: an investigative report from Turkey
por: Ogretmen, Zerrin, et al.
Publicado: (2014)

Orphan drug: Development trends and strategies
por: Sharma, Aarti, et al.
Publicado: (2010)

The portal for rare diseases and orphan drugs
por: Singh, Jatinder
Publicado: (2013)

Impact of orphan drugs on Latvian budget
por: Logviss, Konstantins, et al.
Publicado: (2016)

Are payers treating orphan drugs differently?
por: Cohen, Joshua P., et al.
Publicado: (2014)

What Is the Purpose of the Orphan Drug Act?
por: Herder, Matthew
Publicado: (2017)

Access to Affordable Orphan Medicines in Europe: An EHA Position Paper
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
por: Rodriguez-Monguio, R., et al.
Publicado: (2017)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

An Early Examination of Access to Select Orphan Drugs Treating Rare Diseases in Health Insurance Exchange Plans
por: Robinson, Sandy W., et al.
Publicado: (2014)

Identification of factor XI deficiency in Holstein cattle in Turkey
por: Meydan, Hasan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3k84q3o0gkhds4sp9mv6uutr6c